Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABLYF NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/ARGENRepligen$142.40$123.84$100.99▼$175.77$8.03B1.061.10 million shs981,628 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%RGENRepligen0.00%-3.14%+16.98%+20.90%+12.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/ARGENRepligen$142.40$123.84$100.99▼$175.77$8.03B1.061.10 million shs981,628 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%RGENRepligen0.00%-3.14%+16.98%+20.90%+12.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABLYFAblynx 0.00N/AN/AN/ARGENRepligen 2.88Moderate Buy$164.6415.62% UpsideCurrent Analyst Ratings BreakdownLatest RGEN and ABLYF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026RGENRepligen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)6/3/2026RGENRepligen HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$170.00 ➝ $150.006/2/2026RGENRepligen Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.006/1/2026RGENRepligen Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$160.005/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/7/2026RGENRepligen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/6/2026RGENRepligen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $160.005/6/2026RGENRepligen JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$180.00 ➝ $165.005/5/2026RGENRepligen Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$142.00(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABLYFAblynx$62.73M60.74N/AN/A$2.71 per share18.68RGENRepligen$763.34M10.52$3.42 per share41.68$37.42 per share3.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABLYFAblynx-$122.67MN/AN/AN/AN/AN/AN/AN/AN/ARGENRepligen$48.89M$0.90158.2258.602.746.73%4.88%3.48%8/4/2026 (Estimated)Latest RGEN and ABLYF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026RGENRepligen$0.38$0.48+$0.10$0.15$192.05 million$194.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABLYFAblynxN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABLYFAblynxN/AN/AN/ARGENRepligen0.269.207.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABLYFAblynxN/ARGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipABLYFAblynxN/ARGENRepligen0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABLYFAblynxN/A75.25 millionN/ANot OptionableRGENRepligen2,00056.41 million56.07 millionOptionableRGEN and ABLYF HeadlinesRecent News About These CompaniesRepligen CorporationJuly 3 at 10:51 PM | edition.cnn.comIs Repligen Corporation (RGEN) A Good Stock To Buy Now?July 3 at 10:51 PM | finance.yahoo.comHere’s Why Repligen Corp. (RGEN) Fell 28% in Q1June 30, 2026 | finance.yahoo.comRepligen (NASDAQ:RGEN) CFO Sells $106,285.00 in StockJune 29, 2026 | americanbankingnews.comInsider Selling: Repligen (NASDAQ:RGEN) CFO Sells 733 Shares of StockJune 27, 2026 | insidertrades.comWasatch Advisors LP Purchases New Position in Repligen Corporation $RGENJune 27, 2026 | marketbeat.com2 high-flying stocks on our watchlist and 1 we find riskyJune 25, 2026 | msn.comRepligen jumps as investors revisit strong Q1 results and bioprocessing recovery outlookJune 24, 2026 | quiverquant.comQRepligen Corporation (RGEN) Dropped Following the Earnings ReleaseJune 24, 2026 | insidermonkey.comRepligen (RGEN) Dropped Following the Earnings ReleaseJune 24, 2026 | finance.yahoo.comRepligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells InvestorsJune 22, 2026 | gurufocus.com2 Profitable Stocks on Our Watchlist and 1 Facing ChallengesJune 19, 2026 | finance.yahoo.comRepligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences ToolsJune 19, 2026 | finance.yahoo.comRBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its ViewJune 12, 2026 | insidermonkey.comRepligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Tells InvestorsJune 9, 2026 | gurufocus.comRepligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?June 4, 2026 | zacks.comRepligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 4, 2026 | seekingalpha.comRepligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference TranscriptJune 3, 2026 | seekingalpha.comRepligen Has A Cleaner Recovery Angle, But With High ValuationMay 31, 2026 | seekingalpha.comRepligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF Score: 79/100May 28, 2026 | gurufocus.comGuggenheim Reaffirms Their Hold Rating on Repligen (RGEN)May 25, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGEN and ABLYF Company DescriptionsAblynx OTCMKTS:ABLYF$50.63 0.00 (0.00%) As of 04/30/2019Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.Repligen NASDAQ:RGEN$142.40 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$143.00 +0.60 (+0.42%) As of 07/2/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
